IMBiologics develops immunomodulatory antibody therapeutics utilizing bispecific antibody technology to restore immune system balance in patients with autoimmune diseases and cancer. Their platform accelerates the creation of novel treatment options, addressing the need for effective therapies in these challenging medical areas.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatment options for autoimmune diseases and cancer often fail to fully restore immune system balance, leaving a need for more effective therapies. Existing approaches may not adequately modulate the immune response, leading to incomplete remission or significant side effects.
Solution
IMBiologics is developing a pipeline of immunomodulatory antibody therapeutics designed to re-establish homeostasis in patients suffering from autoimmune disorders and various cancers. The company leverages bispecific antibody technology and proprietary platforms, including IMBolution and ePENDY, to create novel treatment options. These platforms facilitate the discovery and development of antibody-based drugs that can precisely modulate the immune system. IMBiologics' approach aims to address unmet medical needs by developing therapeutics that offer improved efficacy and safety profiles.
Target Audience
The primary target audience includes patients with autoimmune diseases and cancer, as well as healthcare providers seeking innovative treatment options.
Features
- IMBolution Technology: Antibody discovery platform for generating novel immunomodulatory antibodies.
- ePENDY Technology: Bispecific antibody platform for creating therapeutics with dual targeting capabilities.
- Pipeline includes IMB-101, IMB-102, IMB-201, IMB-202, and IMB-401/IMB-402, targeting various autoimmune diseases and cancers.